top of page
Anchor 5

The Casanova/Moll/Uras Lab: Cancer Research

Emilio.jpg

Emilio Casanova

images.jpg

Herwig Moll

Iris.jpg

Iris Uras

Anchor 1

Research interests

Our research aims to understand how oncogenic signaling pathways and interactions between tumor cells and the tumor immune microenvironment (TIME) drive lung cancer development and influence therapeutic responses. We focus on identifying the molecular and cellular mechanisms underlying tumor progression, immune escape and therapeutic vulnerabilities, with the ultimate goal of developing improved treatment strategies.

We primarily investigate KRAS- and EGFR-driven lung adenocarcinoma, two major molecular subtypes with distinct oncogenic drivers and therapeutic challenges.

mouse.png

KRAS-driven lung adenocarcinoma

We investigate therapeutic vulnerabilities in KRAS-driven tumors by studying oncogenic signaling pathways, cellular dependencies and metabolic adaptations. A particular focus is on understanding how KRAS-driven tumor cells shape the tumor immune microenvironment and how these interactions influence tumor progression and responses to immunotherapy, including immune checkpoint blockade.

​

EGFR-driven lung adenocarcinoma

We investigate the molecular and cellular mechanisms underlying tumor progression and responses to EGFR-targeted therapies. In particular, we study how tumor–immune interactions influence the persistence of residual tumor cells during treatment and their subsequent progression to relapse. Our aim is to identify immune mechanisms and therapeutic vulnerabilities that could improve the durability of targeted therapies.

​

Experimental approaches

Our research combines genetically engineered mouse models of human cancer, genetically modified human and mouse cancer cell lines, tumor transplantation models and human tumor specimens. These complementary approaches allow us to investigate tumor development, dissect tumor–immune interactions and evaluate novel therapeutic strategies.

lung1.png
lung_2.jpg

Selected publications

Anchor 2

Uras, IZ,  et al., KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors. 2026. NPJ Precis Oncol. Available at:  https://doi.org/10.1038/s41698-025-01242-8

​

Luca, AC,  et al., Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma. 2025. Cancer Letters. Available at:  https://doi.org/10.1016/j.canlet.2025.217733

 

Caratti, B. et al., 2022. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Science Signaling. Available at: DOI: 10.1126/scisignal.abm4452 

​

Breitenecker, K. et al., 2021. Downregulation of A20 promotes immune escape of lung adenocarcinomas. Science Translational Medicine. Available at: https://doi.org/10.1126/scitranslmed.abc3911

​

Mohrherr, J. et al., 2019. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. International Journal of Cancer. Available at: https://doi.org/10.1002/ijc.32624

​

Moll, H.P. et al., 2018. Afatinib restrains K-RAS-driven lung tumorigenesis. Science Translational Medicine. Available at: http://dx.doi.org/10.1126/scitranslmed.aao2301

​

Grabner, B. et al., 2015. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications. Available at: http://dx.doi.org/10.1038/ncomms7285

​

Musteanu, M. et al., 2012. A mouse model to identify cooperating signaling pathways in cancer. Nature Methods. Available at: https://doi.org/10.1038/nmeth.2130

​

​

Group members

Anchor 3
group pic 3 05 26.jpg

From left to right: Ritesh Narwal, Sadaf Keshavarz, Emilio Casanova, Faith David, Eva Putz, Lena Vlasitz, Masa Beres, Christoph Trenk, Marija Trkulja, Jaqueline Horvath, Herwig  Moll, Sarah Trouvilliez, Aaron Rauscher, Pauline Sieger, Iris Uras, Michael Machtinger and Monika Homolya

 

Paulina leaving_edited.jpg

Pauline goodbye cake party. 2026

center retreat 2026.jpg

Center retreat. 2026

iris oegcho prize 2026.jpg

Iris Uras received the Innovation Award from the Austrian Society of Oncology (OeGHO). Congratulations!!!. 2026

Yanira_defensio_edited.png

Yanira defending her diploma. Congratulations!  2026

goodby_Yanira_Kati_2026_edited.png

Good bye party of Yanira and Kati. Good luck for the future. 2026

Sarah_grant_2026_edited.png

Sarah´s grant celebration! 2026

Iris_dora2_2026_edited.jpg

Iris Uras reciving the Dora Brücke-Teleky prize! 2026

Monika 2 EACR 2026.JPG

Monika Homolya awarded with a travel grant! EACR 2026

Group EACR 2026_edited.png

EACR meeting, Budapest, 2026

2010
Monika_Faith_doc_grant_2024.jpg
retreat 2024_edited.jpg

Contact

Anchor 4

Emilio Casanova

Medical University of Vienna

Center for Physiology and Pharmacology 

Institute of Pharmacology, first floor

Währinger Str. 13a

A-1090 Vienna,

Austria

Phone:  43 1 40160 31341

Fax: 43 1 40160 931300

Email

MUW.jpg
bottom of page